Promising rectal cancer study
A scientist comments on the evolving treatment of rectal cancer in light of findings from a study that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer.
Materials provided by UNC Lineberger Comprehensive Cancer Center. Note: Content may be edited for style and length.
Source link aaaaa